Deal continues consolidation trend, based on portfolio expansion and simplifying supply chains
US-based generic drugmakers Amneal and Impax have agreed to merge, through an all-shares deal that the companies claim will push the combined firm into the top five US generics firms by revenue.
The new Amneal will have a strengthened supply chain and an expanded product portfolio, with around 165 product families on the market, and a further 300 in development across a broad range of therapeutic areas and dosage forms. The companies also expect to be able to make $200 million (£150 million) in annual cost savings within two years of completing the deal.
As Business editor, Phillip's aim is to highlight to readers the exciting and innovative chemistry going on in the commercial sector, as well as keeping them abreast of trends and developments in the world of chemistry businesses.View full profile
No comments yet